#$%^&*AU2020203484A120200618.pdf#####Abstract An application of a fullerene structure in the preparation of medications for treating Parkinson's disease. The fullerene structure comprises at least one of the following active ingredient groups: a fullerene, a metallofullerene, and a composition of the fullerene and the metallofullerene； an oil-soluble fullerene, an oil-soluble metallofullerene, and a composition of the oil-soluble fullerene and the oil-soluble metallofullerene； a water-soluble fullerene, a water-soluble metallofullerene, and a composition of the water-soluble fullerene and the water-soluble metal-lofullerene； the medicinal esters of the nine elements, or the medicinal salts of the nine elements.1/15 2000 • 1000 *w e 0 m-1000 -2000 320 322 324 326 Magnetic field (Guass) Fig.1 30002000 C 1000 4 00 -1000 -2000 -3000320 322 324 326 Magnetic field (Guass) Fig. 2
